CEL-SCI Corp.
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.59%241.171.3%$849.07m
MRNAModerna, Inc. -2.50%65.480.0%$698.94m
IMMUImmunomedics, Inc. 0.00%85.1711.0%$669.53m
NVAXNovavax, Inc. 0.78%102.3696.5%$609.87m
GILDGilead Sciences, Inc. -0.75%62.621.0%$568.87m
ILMNIllumina, Inc. -0.07%272.803.5%$450.73m
REGNRegeneron Pharmaceuticals, Inc. -0.87%560.262.7%$434.79m
BIIBBiogen, Inc. -1.00%269.491.6%$334.11m
VRTXVertex Pharmaceuticals, Inc. -0.69%262.011.9%$319.69m
ALXNAlexion Pharmaceuticals, Inc. -0.31%112.082.0%$278.11m
SRNESorrento Therapeutics, Inc. -3.38%9.281.5%$259.93m
MNTAMomenta Pharmaceuticals, Inc. 0.12%52.353.0%$205.28m
SGENSeattle Genetics, Inc. -1.48%176.616.0%$199.41m
VXRTVaxart, Inc. -4.94%6.840.0%$194.48m
BMRNBioMarin Pharmaceutical, Inc. -1.86%76.974.3%$193.93m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.